Dose the first patient with intermediate risk non-muscle invasive bladder cancer in the SURF302 study
Delivered after the deadline (45 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 May 2025
- Due
- 30 Jun 2025
- Delivered
- 14 Aug 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“SURF302: dose first IR NMIBC patient with TYRA-300 – Q2 2025”
What we found
Evidence strength A What the grades mean
The company announced in August 2025 that it had dosed the first patient in the SURF302 study, which occurred after the Q2 2025 deadline.
-
A Tyra Biosciences, Inc. 8-K filed 2025-08-14
“Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights - Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC)” ✓ confirmed on the page
-
A Tyra Biosciences, Inc. 10-K filed 2026-03-02
“In August 2025, we announced that the first patient was dosed in SURF302” ✓ confirmed on the page
Market reaction: the shares moved +0.8% against the S&P 500 over the three sessions around the disclosure (13 Aug 2025 to 18 Aug 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Dose
- Deliverable
- first patient dosed in SURF302 study
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Tyra Biosciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-TYRA-002086 · Corrections policy